The future of multiple sclerosis treatments

被引:8
作者
Coclitu, Catalina [1 ]
Constantinescu, Cris S. [2 ]
Tanasescu, Radu [2 ,3 ]
机构
[1] Univ Hosp, Dept Neurol, Bucharest, Romania
[2] Univ Nottingham, Acad Clin Neurol, Div Clin Neurosci, Nottingham, England
[3] Univ Med & Pharm Carol Davila, Colentina Hosp, Dept Neurol Neurosurg & Psychiat, Bucharest, Romania
关键词
Multiple sclerosis; immunomodulation; monoclonal antibodies; remyelination; repurposing; STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; DISEASE-MODIFYING THERAPIES; HIGH-YIELD PROCESS; HIGHLY-ACTIVE MS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; CUTANEOUS ADVERSE EVENTS;
D O I
10.1080/14737175.2016.1243056
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: There are not many conditions in which the last few decades have brought such a major change in the landscape of treatments as is the case of multiple sclerosis (MS). A number of disease modifying treatments (DMTs) are presently available for the treatment of the inflammatory phase of this disabling disease; however, the need for treating neurodegeneration and halting the progression of disability is still unmet.Areas covered: In this paper we review the available information on existing and emerging DMTs and we discuss their place within the context of different treatment strategies in MS,Expert commentary: The future of MS treatments should include the development of new treatment strategies tackling disease progression, together with a better understanding of the side-effects and the best sequential strategy of implementation of available and emerging drugs.
引用
收藏
页码:1341 / 1356
页数:16
相关论文
共 211 条
  • [1] Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice
    Abramowski, Pierre
    Krasemann, Susanne
    Ernst, Thomas
    Lange, Claudia
    Ittrich, Harald
    Schweizer, Michaela
    Zander, Axel R.
    Martin, Roland
    Fehse, Boris
    [J]. STEM CELLS AND DEVELOPMENT, 2016, 25 (15) : 1134 - 1148
  • [2] Agency EM, 2011, REF MARK AUTH MOV CL
  • [3] Drugs in Development for Relapsing Multiple Sclerosis
    Ali, Rehiana
    Nicholas, Richard St John
    Muraro, Paolo Antonio
    [J]. DRUGS, 2013, 73 (07) : 625 - 650
  • [4] Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
    Alping, Peter
    Frisell, Thomas
    Novakova, Lenka
    Islam-Jakobsson, Protik
    Salzer, Jonatan
    Bjorck, Anna
    Axelsson, Markus
    Malmestrom, Clas
    Fink, Katharina
    Lycke, Jan
    Svenningsson, Anders
    Piehl, Fredrik
    [J]. ANNALS OF NEUROLOGY, 2016, 79 (06) : 950 - 958
  • [5] AMOR S, 1994, J IMMUNOL, V153, P4349
  • [6] [Anonymous], 2016, CONCERTO ARPEGGIO TR
  • [7] Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride
    Arun, Tarunya
    Tomassini, Valentina
    Sbardella, Emilia
    de Ruiter, Michiel B.
    Matthews, Lucy
    Leite, Maria Isabel
    Gelineau-Morel, Rose
    Cavey, Ana
    Vergo, Sandra
    Craner, Matt
    Fugger, Lars
    Rovira, Alex
    Jenkinson, Mark
    Palace, Jacqueline
    [J]. BRAIN, 2013, 136 : 106 - 115
  • [8] Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update
    Ascherio, Alberto
    Munger, Kassandra L.
    [J]. SEMINARS IN NEUROLOGY, 2016, 36 (02) : 103 - 114
  • [9] Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
    Atkins, Harold L.
    Bowman, Marjorie
    Allan, David
    Anstee, Grizel
    Arnold, Douglas L.
    Bar-Or, Amit
    Bence-Bruckler, Isabelle
    Birch, Paul
    Bredeson, Christopher
    Chen, Jacqueline
    Fergusson, Dean
    Halpenny, Mike
    Hamelin, Linda
    Huebsch, Lothar
    Hutton, Brian
    Laneuville, Pierre
    Lapierre, Yves
    Lee, Hyunwoo
    Martin, Lisa
    McDiarmid, Sheryl
    O'Connor, Paul
    Ramsay, Timothy
    Sabloff, Mitchell
    Walker, Lisa
    Freedman, Mark S.
    [J]. LANCET, 2016, 388 (10044) : 576 - 585
  • [10] Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned
    Atkins, Harold L.
    Freedman, Mark S.
    [J]. NEUROTHERAPEUTICS, 2013, 10 (01) : 68 - 76